129 related articles for article (PubMed ID: 28078583)
1. Generation and Application of Bioluminescent CD95 Ligand Fusion Proteins.
Lang I; Kums J; Wajant H
Methods Mol Biol; 2017; 1557():63-77. PubMed ID: 28078583
[TBL] [Abstract][Full Text] [Related]
2. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
[TBL] [Abstract][Full Text] [Related]
3. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95.
Assohou-Luty C; Gerspach J; Siegmund D; Müller N; Huard B; Tiegs G; Pfizenmaier K; Wajant H
J Mol Med (Berl); 2006 Sep; 84(9):785-97. PubMed ID: 16924474
[TBL] [Abstract][Full Text] [Related]
4. CD95 Stimulation with CD95L and DISC Analysis.
Le Gallo M; Legembre P
Methods Mol Biol; 2017; 1557():11-18. PubMed ID: 28078578
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence resonance energy transfer analysis of proapoptotic CD95-EGF receptor interactions in Huh7 cells.
Eberle A; Reinehr R; Becker S; Häussinger D
Hepatology; 2005 Feb; 41(2):315-26. PubMed ID: 15660394
[TBL] [Abstract][Full Text] [Related]
7. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
[TBL] [Abstract][Full Text] [Related]
9. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
10. Production of the Non-apoptotic Metalloprotease-Cleaved CD95L and Its Cytotoxic Recombinant Counterpart Designed Ig-CD95L.
Lepvrier E; Martin S; Collet B
Methods Mol Biol; 2017; 1557():1-10. PubMed ID: 28078577
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
12. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand.
Ng CS; Lo ST; Chan JK
Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926
[TBL] [Abstract][Full Text] [Related]
13. Differential down-regulation of CD95 or CD95L in chronically HIV-infected cells of monocytic or lymphocytic origin: cellular studies and molecular analysis by quantitative competitive RT-PCR.
Pinti M; Pedrazzi J; Benatti F; Sorrentino V; Nuzzo C; Cavazzuti V; Biswas P; Petrusca DN; Mussini C; De Rienzo B; Cossarizza A
FEBS Lett; 1999 Sep; 458(2):209-14. PubMed ID: 10481067
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
[TBL] [Abstract][Full Text] [Related]
15. CD95-tyrosine nitration inhibits hyperosmotic and CD95 ligand-induced CD95 activation in rat hepatocytes.
Reinehr R; Görg B; Höngen A; Häussinger D
J Biol Chem; 2004 Mar; 279(11):10364-73. PubMed ID: 14679192
[TBL] [Abstract][Full Text] [Related]
16. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of cells with combined apoptosis and proliferation markers in thyroid tissue specimens from patients with cancer, adenoma, and autoimmune diseases.
Kazakov SP; Zabotina TN; Korotkova OV; Dzabarov AK; Kazantseva IA
Bull Exp Biol Med; 2011 Feb; 150(4):453-8. PubMed ID: 22268042
[TBL] [Abstract][Full Text] [Related]
18. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death.
Stohl W; Xu D; Starling GC; Casali P; Kiener PA
Cell Immunol; 2000 Jul; 203(1):1-11. PubMed ID: 10915556
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.
Moers C; Warskulat U; Müschen M; Even J; Niederacher D; Josien R; Koldovsky U; Beckmann MW; Häussinger D
Int J Cancer; 1999 Feb; 80(4):564-72. PubMed ID: 9935158
[TBL] [Abstract][Full Text] [Related]
20. CD95/Fas ligand induced toxicity.
Haluck-Kangas A; Peter ME
Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
